Skip to content
Clinical Trials – home
SwedenBack to Sweden

Clinical trials in Saltsjöbaden – page 5

771 clinical trials in Saltsjöbaden, Sweden across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SwedenOur site in SwedenKliniska-Provningar.se(opens in a new tab)
Saltsjöbaden at a glance
771
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

771 trials in Saltsjöbaden

Open in trial search

A Study of Baricitinib to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes

Registered drug
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years
  • Substances:Baricitinib
  • Sponsor:Eli Lilly & Co.

Long‑Term Safety and Efficacy Study of Danicamtiv in Adults with Symptomatic Genetic and Familial Dilated Cardiomyopathy

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Danicamtiv
  • Sponsor:Kardigan Inc.

A study of the safety and efficacy of AC01 in patients with heart failure with reduced ejection fraction

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Drocamorelin
  • Sponsor:AnaCardio AB

Study of AZD6234 (lenbelintide) Added to Incretin Therapy in Adults with Obesity or Overweight and a Weight‑Related Comorbidity, With or Without Type 2 Diabetes

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:AZD6234
  • Sponsor:AstraZeneca AB

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Belumosudil
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Safety and Pharmacodynamic Study of Subcutaneous RBD1119 in Adults with Coronary Artery Disease

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:RBD1119 sodium
  • Sponsor:Ribocure Pharmaceuticals AB

A double‑blind, placebo‑controlled trial of oral BI 1015550 in patients with systemic sclerosis

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Nerandomilast
  • Sponsor:Boehringer Ingelheim Espana S.A.

Effect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

A Phase III Study of Elafibranor in Adults with Primary Sclerosing Cholangitis to Assess Efficacy and Safety

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Elafibranor
  • Sponsor:Ipsen Bioscience Inc.

Zodasiran for Adolescents With Homozygous Familial Hypercholesterolemia: A Phase 3 Study of Efficacy and Safety

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years
  • Substances:Zodasiran
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Efficacy and safety of votoplam in adults with Huntington’s disease: a randomized, double‑blind, placebo‑controlled Phase 3 trial

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Votoplam
  • Sponsor:Novartis Pharma AG

A study of hydroxyurea added to standard drug combination to assess safety and effectiveness in adults with relapsed or refractory acute myeloid leukemia

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Karolinska University Hospital

Other cities in Sweden

The busiest research cities in the country

All 66 cities in Sweden

Clinical research in Saltsjöbaden

What the registry says about research in the country

01 Diseases [C] - Virus Diseases [C02]

In Saltsjöbaden, clinical research in this area focuses on RSV infection and the immune response to prevention-focused interventions. These studies are looking at how well a new approach can support protection against respiratory viral illness in older adults.

  • RSV infection
  • Respiratory tract diseases
  • Evaluating immune protection against viral infection

The work is centered on understanding whether the intervention can strengthen the body’s defense against RSV and help reduce the impact of this common respiratory virus.

02 Diseases [C] - Respiratory Tract Diseases [C08]

This research field covers trials aimed at preventing or reducing illness related to respiratory tract diseases, with a strong focus on RSV infection. The main goal is to assess how effective a vaccine-based strategy may be in older adults.

  • Respiratory tract disease prevention
  • RSV antibody response
  • Testing a new preventive therapy

These studies help clarify whether the intervention can improve protection in populations more vulnerable to severe respiratory infections.

03 Diseases [C] - Bacterial Infections and Mycoses [C01]

Clinical trials in this therapeutic area are examining treatment options for Diabetic Foot Ulcer, a wound complication where infection control and healing are major concerns. The research is focused on finding better local antimicrobial care to support complete wound closure.

  • Diabetic Foot Ulcer
  • Bacterial infection management
  • Improving wound healing outcomes

In Sweden, this line of research is comparing approaches that may help clinicians choose more effective treatments for difficult-to-heal ulcers.

04 Diabetic Foot Ulcer

The trial activity around Diabetic Foot Ulcer is aimed at evaluating how well local antimicrobial agents help wounds heal. It is a practical, patient-centered area of research focused on treatment effectiveness and recovery.

  • Local antimicrobial treatment
  • Time to healing
  • Wound care and infection control

These studies are intended to improve everyday care for people living with chronic foot ulcers linked to diabetes.

05 RSV infection

Research on RSV infection is centered on prevention and immune response in older adults, especially those at higher risk of severe disease. The trials are assessing whether a new protective strategy can generate helpful neutralizing antibodies.

  • Older adult respiratory health
  • Immune response to RSV
  • Preventive vaccine research

This work supports better understanding of how to reduce the burden of RSV in aging populations.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.